With our improved understanding and progress of cancer immunotherapy, including the anti-PD-1/PD-L1 and anti-CTLA4 monoclonal antibody (mAb)-based therapies as well as the expansion of immunotherapeutic clinical trials on various types of cancers, the prospect of developing an effective treatment for GI cancers has been enhanced [2]. The gene discussed is CTLA4; the disease is cancer.